Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10601
Country/Region: Ethiopia
Year: 2017
Main Partner: Addis Ababa University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $438,390 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $43,514
Care: TB/HIV (HVTB) $10,341
Care: Pediatric Care and Support (PDCS) $18,859
Health Systems Strengthening (OHSS) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $22,972
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $13,674
Treatment: Adult Treatment (HTXS) $287,997
Treatment: Pediatric Treatment (PDTX) $41,033
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 27
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 20
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 30
GEND_GBV Number of people receiving post-GBV care 2018 50
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive 2018 44
PMTCT_ART Already on ART at beginning of current pregnancy 2018 72
PMTCT_ART New on ART 2018 9
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 81
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 5,606
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 85
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 16
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 65
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 3
PMTCT_STAT By Age (Numerator): 15-19 2018 280
PMTCT_STAT By Age (Numerator): 20-24 2018 1,962
PMTCT_STAT By Age (Numerator): 25-49 2018 3,364
PMTCT_STAT By Number of known positives: 15-19 2018 4
PMTCT_STAT By Number of known positives: 20-24 2018 27
PMTCT_STAT By Number of known positives: 25-49 2018 45
PMTCT_STAT By Number of new negative: 15-19 2018 276
PMTCT_STAT By Number of new negative: 20-24 2018 1,932
PMTCT_STAT By Number of new negative: 25-49 2018 3,312
PMTCT_STAT By Number of new positives: 20-24 2018 3
PMTCT_STAT By Number of new positives: 25-49 2018 7
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 5,606
PMTCT_STAT_den By Age (Denominator): <15-19 2018 295
PMTCT_STAT_den By Age (Denominator): 20-24 2018 2,065
PMTCT_STAT_den By Age (Denominator): 25-49 2018 3,541
PP_PREV Age/sex: 10-14 Female 2018 5
PP_PREV Age/sex: 15-19 Female 2018 53
PP_PREV Age/sex: 15-19 Male 2018 24
PP_PREV Age/sex: 20-24 Female 2018 142
PP_PREV Age/sex: 20-24 Male 2018 73
PP_PREV Age/sex: 25-49 Female 2018 316
PP_PREV Age/sex: 25-49 Male 2018 163
PP_PREV Age/sex: 50+ Female 2018 15
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 791
PP_PREV Sum of Age/Sex disaggregates 2018 791
TB_PREV By Age/Sex (Numerator): <15, Female 2018 15
TB_PREV By Age/Sex (Numerator): <15, Male 2018 16
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 205
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 134
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 370
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 370
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 411
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 16
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 18
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 228
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 149
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 411
TX_CURR Aggregated Age/Sex: <15 Female 2018 198
TX_CURR Aggregated Age/Sex: <15 Male 2018 210
TX_CURR Aggregated Age/Sex: 15+ Female 2018 2,779
TX_CURR Aggregated Age/Sex: 15+ Male 2018 1,822
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 5,009
TX_CURR Sum of Aggregated Age/Sex <15 2018 408
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 4,601
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 5,009
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 18
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 20
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 253
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 166
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 457
TX_NEW Pregnancy status 2018 15
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 457
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 6,196
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 4,783
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 73
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 34
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 77
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 35
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,601
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,156
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,049
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 758
TX_PVLS Numerator: Indication: Routine 2018 2,800
TX_PVLS Numerator: Indication: Targeted 2018 1,983
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 104
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 45
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 110
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 47
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,779
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,779
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,166
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 1,166
TX_PVLS_den Denominator: Indication: Routine 2018 3,159
TX_PVLS_den Denominator: Indication: Targeted 2018 3,037
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 17
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 19
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 230
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 151
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 417
TX_RET Numerator by Status: Pregnant 2018 14
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 457
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 18
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 20
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 253
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 166
TX_RET_den Denominator by Status: Pregnant 2018 15
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 4,508
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 72
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 4
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 30
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 34
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 225
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 270
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 1,848
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 2,165
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 203
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 41
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 162
TX_TB_den Denominator: By Screen Result: Negative 2018 4,057
TX_TB_den Denominator: By Screen Result: Positive 2018 451
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 406
Cross Cutting Budget Categories and Known Amounts Total: $2,710
Gender: Gender Based Violence (GBV) $2,710
GBV Prevention
Implementation
Capacity building